However, different limitations remain, and future research is needed to better understand how STING activation impacts the tumor microenvironment, identify effective combination strategies, and determine the best tumor types for STING agonist use to enhance clinical outcomes and overcome immunosuppressive effects. Here, STING1 is linked to neoplasm.